ReviewReported positiveLimited evidenceTier 4 · clinical
Drugs · Jun 2026 · regulatory approval summary
Relacorilantepithelial ovarian cancerfallopian tube cancerprimary peritoneal cancerpancreatic cancerprostate cancer Relacorilant is a non-steroidal, selective glucocorticoid receptor antagonist being developed for several solid tumours and Cushing syndrome. The article reports that relacorilant received its first approval in the USA on 25 March 2026 for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer after 1-3 prior systemic regimens (at least one including bevacizumab). The article summarizes development milestones leading to this approval.
Studied with: nab-paclitaxel.
Key findings
- Relacorilant is a non-steroidal, selective glucocorticoid receptor II antagonist developed by Corcept Therapeutics.
- Relacorilant received first approval in the USA on 25 March 2026.
- Approval is for use in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.
- Relacorilant is being developed for various solid tumours including ovarian, fallopian tube, peritoneal, pancreatic and prostate cancers, as well as for Cushing syndrome.
- The article summarizes milestones in the development of relacorilant leading to this approval.
Limitations: Abstract provides no efficacy or safety outcome data or numeric results from trials.; No trial design, sample size, or methods are reported in the abstract.; This is an approval/summary article, not primary trial data.; Geographic scope limited to a USA approval; supporting evidence is not detailed in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
Animal studyReported positivePreclinical onlyTier 2 · animal
Science (New York, N.Y.) · Mar 2026
pancreatic cancer
The authors report that drugs which inhibit KRAS signaling delayed the development of pancreatic cancer in mice. The abstract does not specify which drugs, doses, timing, sample size, or statistical measures were used. This is an animal study showing a preclinical anticancer effect of KRAS-pathway inhibition.
Key findings
- In mice, drugs that inhibit KRAS signaling delayed the development of pancreatic cancer.
Limitations: Study was performed in mice (animal model) and results may not translate to humans.; Abstract provides no details on which specific drugs were used, doses, timing, sample sizes, control groups, or statistical significance.; No quantitative results or methodology are reported in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
ReviewInconclusiveLimited evidenceTier 4 · clinical
World journal of gastroenterology · Nov 2025 · narrative review
pancreatic neoplasmspancreatic cancer
This is a narrative review summarizing recent progress in pancreatic cancer up to 2025. The authors discuss advances in prevention and early detection, better molecular understanding, more effective systemic therapies, improved quality of life and surgical outcomes, and the role of artificial intelligence.
Key findings
- Pancreatic cancer continues to have a very poor prognosis due to late presentation, aggressive biology, and resistance to chemotherapy.
- Areas of progress highlighted include prevention and early detection strategies.
- The review notes refinements in molecular understanding of pancreatic cancer that may inform therapy.
- Identifying more effective systemic therapies and improving quality of life and surgical outcomes are described as progress areas.
- The authors emphasize the importance of technological advances, particularly artificial intelligence.
Limitations: Narrative review; no original experimental or clinical data are reported in the abstract.; Abstract provides no methods, selection criteria, or systematic search details.; No quantitative results or specific studies/metrics are reported in the abstract.; Broad scope limits detail on any single intervention, biomarker, or therapy..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewInconclusiveLimited evidenceTier 4 · clinical
ESMO open · Apr 2025 · ESMO Clinical Practice Guideline Express Update
metastatic pancreatic cancer
This is an ESMO clinical practice guideline express update addressing recent developments in managing metastatic pancreatic cancer. The update was issued following the approval of first-line nanoliposomal irinotecan (NALIRIFOX) and provides updated first- and second-line treatment recommendations and an updated management algorithm.
Key findings
- This ESMO Clinical Practice Guideline Express Update addresses developments in the management of metastatic pancreatic cancer.
- It has been issued following the approval of first-line nanoliposomal irinotecan (NALIRIFOX regimen).
- Updated first- and second-line treatment recommendations are provided.
- An updated management algorithm for metastatic pancreatic cancer is also included.
Limitations: Abstract-only summary of a guideline; no methodological details or evidence tables are provided in the abstract.; No primary patient-level data, sample sizes, or outcome measures are reported in the abstract.; No information on funding, conflicts of interest, or the strength/grade of specific recommendations is provided in the abstract..
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismReported positiveLimited evidenceTier 3 · early human
Oncology research · Feb 2025 · Systematic review with bioinformatic analyses (PRISMA-guided literature search and database analyses)
ovarian cancersarcomapancreatic cancer
This systematic review and bioinformatic analysis examined the relationships among the long noncoding RNA ZFAS1, microRNAs, and mRNAs in cancer. The authors report that ZFAS1 often acts as a sponge for multiple miRNAs, highlight a strong negative correlation with miR-150-5p, and find that higher ZFAS1 expression is associated with poorer overall survival in ovarian, sarcoma, and pancreatic cancers. They also identify involvement of signaling pathways including STAT3 and Wnt/β-catenin and roles in RNA binding and ribonucleoprotein formation.
Reported effect: correlation miR-150-5p vs ZFAS1 -0.346, p=3.27e-16
Key findings
- ZFAS1 serves as a sponge for numerous miRNAs (ceRNA activity).
- miR-150-5p is significantly correlated with ZFAS1 across multiple databases (p-value = 3.27e-16, R-value = -0.346).
- Kaplan-Meier survival analysis indicated an association between ZFAS1 expression levels and worse overall prognosis in ovarian, sarcoma, and pancreatic cancers.
- ZFAS1/miRNAs/mRNAs axis involves signaling pathways including STAT3, SKA1, LPAR1, and Wnt/β-catenin.
- ZFAS1 is implicated in molecular processes such as RNA binding and ribonucleoprotein formation.
Limitations: This paper is a systematic review and bioinformatic analysis rather than primary experimental or clinical data.; Findings are largely observational and correlative; causality is not established.; No sample sizes or patient-level details are reported in the abstract for the survival analyses.; Potential heterogeneity and publication bias across the included studies are not detailed in the abstract.; No experimental validation of the bioinformatic predictions is reported in the abstract..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewReported positiveModerate evidenceTier 4 · clinical
The oncologist · Feb 2025 · narrative review
glioblastomagrade 4 gliomapediatric central nervous system tumorsbrain metastaseslung cancerovarian cancerpancreatic cancergastric cancerhepatic cancer
This review summarizes Tumor Treating Fields (TTFields), a noninvasive device that delivers alternating electric fields to tumors. It reports mechanisms of action (mitotic disruption, DNA replication/DNA damage response effects, reduced motility, and immune enhancement), notes FDA approval for newly diagnosed and recurrent glioblastoma, and describes clinical data showing efficacy across patient groups, a tolerable safety profile, and correlations between higher device usage/dose and longer survival. The review also highlights promising pilot studies combining TTFields with immunotherapy and radiotherapy and ongoing studies in pediatric patients and other solid tumors.
Studied with: immunotherapy, radiotherapy.
Key findings
- TTFields is a locoregional, noninvasive, portable device that delivers alternating electric fields to tumors through arrays placed on the skin.
- Based on global pivotal randomized phase III clinical studies, TTFields therapy (Optune Gio) is FDA-approved for newly diagnosed and recurrent glioblastoma and CE-marked for grade 4 glioma.
- Multimodal mechanisms include disruption of cancer cell mitosis, inhibition of DNA replication and damage response, interference with cell motility, and enhancement of systemic adaptive immunity.
- Clinical data show efficacy in a broad range of patients with a tolerable safety profile, including high-risk subpopulations.
- New analyses confirmed that overall and progression-free survival positively correlated with increased device usage and dose of TTFields at the tumor site.
- Pilot/early phase clinical studies of TTFields with immunotherapy and with radiotherapy in newly diagnosed GBM have shown promise; new pivotal studies are planned.
- Recent and ongoing studies are evaluating TTFields in pediatric care, other CNS tumors, brain metastases, and several advanced-stage solid tumors (lung, ovarian, pancreatic, gastric, hepatic).
Limitations: This article is a narrative review rather than original research; the abstract does not present new primary numeric results.; Abstract provides no numeric effect sizes, confidence intervals, p-values, or sample sizes for the studies discussed.; Claims about broader tumor types, pediatric use, and combinations are based on pilot/early-phase studies and ongoing research and thus remain preliminary.; Potential for selection or publication bias in the reviewed literature is not addressed in the abstract.; Funding sources and potential conflicts of interest are not reported in the abstract..
The review focuses on TTFields therapy's mechanisms, clinical efficacy/safety data in glioblastoma, and exploratory uses in other CNS and solid tumors.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
ReviewMechanismInconclusiveLimited evidenceTier 4 · clinical
Familial cancer · Aug 2024 · review
pancreatic cancer
This narrative review discusses current pancreatic surveillance and the need for better biomarkers to expand early detection beyond high-risk groups. It notes that current surveillance uses annual endoscopic ultrasound and MRI/MRCP for people with familial/genetic risk, and that accurate, inexpensive, safe biomarkers remain elusive. The authors highlight newer approaches such as personalized gene tests and artificial intelligence to integrate complex biomarker data as promising directions.
Key findings
- Pancreatic surveillance can detect early-stage pancreatic cancer and achieve long-term survival in some cases.
- Current surveillance involves annual endoscopic ultrasound (EUS) and MRI/MRCP and is recommended only for individuals who meet familial/genetic risk criteria.
- More accurate, inexpensive, and safe biomarkers are needed to improve early detection and expand access, but have so far been elusive.
- Newer approaches — gene tests to personalize biomarker interpretation and artificial intelligence to integrate complex biomarker data — offer promise for future clinically useful biomarkers.
Limitations: This is a narrative review rather than original primary data from a clinical study.; No new validated biomarkers or quantitative diagnostic performance metrics are reported in the abstract.; Recommendations are general and do not provide prospectively validated protocols for broader population screening.; Abstract does not report study methods, search strategy, or systematic review/meta-analysis methods..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text